This document presents a consolidated summary of urgent activities
required to advance preparedness, as elaborated in each country's
national plan, with a particular focus on Priority 1 countries. It
presents the estimated requirements, needs, and gaps for each of the
Priority 1 countries and a ...summary for Priority 2 countries, as
aligned for the period of July to December 2019.
more
Immer wieder hören wir – in der inzwischen jahrzehntelangen
Lobbyarbeit der BAG – aus der Politik die Bitte, das Problem
der medizinischen Unterversorgung von Menschen ohne Papiere
zu „bebildern“: Wer sind diese Menschen? Wo liegen die Probleme in der gesundheitlichen Versorgung? Vor ...welchen praktischen Problemen, d.h. Sachzwängen, bürokratischen und rechtlichen Hürden stehen die Helfenden in den Anlaufstellen, die dort Hilfe leisten, wo der Zugang zum Gesundheitssystem versperrt ist? Die hier geschilderten Fälle aus der medizinischen Praxis sollen das humanitäre Problem besser nachvollziehbar machen.
more
Jamieson D and Kellerman S. Journal of the International AIDS Society 2016, 19:20917 http://www.jiasociety.org/index.php/jias/article/view/20917 | http://dx.doi.org/10.7448/IAS.19.1.20917
Vaincre le Sida par Tous, une Riposte pour Tous
Le Plan Stratégique National de Lutte contre le Sida (PSN) 2018-2022 sera le cadre unique pour tous les acteurs de la lutte contre le sida au Sénégal. Il constitue la référence pour la programmation des activités aux niveaux national et régio...nal, et sera l’outil indispensable pour l’harmonisation et l’alignement des partenaires. Ce plan traduit la vision et les engagements du Gouvernement du Sénégal à maintenir les acquis et à orienter la riposte vers l’élimination du sida en utilisant toutes les opportunités et ressources, aussi bien domestiques qu’internationales.
more
Les résultats des enquêtes réalisées en Afrique subsaharienne montrent que seulement 12 % des hommes et 10 % des femmes ont bénéficié d’un dépistage du VIH et en ont reçu le résultat. En RCA, selon le rapport de l’Accès Universel 2009, 4 % des personnes de plus de 15 ans ont fait un t...est de dépistage dans les 12 derniers mois dans le pays et qui sont revenus chercher leurs résultats.
more
Accessed on 20.03.2020
Il est troublant de se voir changer. Cela soulève toutes sortes d’interrogations simples ou complexes, audacieuses, parfois angoissantes, toujours importantes. Des questions qui touchent à l’identité, au corps, à la relation à l’autre, à la sexualité et à l’...amour. L’adolescence est une période de recherche, de découvertes, d’essais et de remises en question. Cette brochure propose des pistes de réponses et des éléments de réflexion pour combattre les idées reçues, les préjugés et les fausses croyances souvent sources de souffrances pour soi-même et pour les autres.
more
2nd edition, July 2021. This WHO and HRP guideline is designed to help countries make faster progress, more equitably, on the screening and treatment of cervical cancer. It includes some important shifts in WHO’s recommended approaches to cervical screening, and includes a total of 23 recommendati...ons and 7 good practice statements.
Among the 23 recommendations, 6 are identical for both the general population of women and for women living with HIV and 12 are different and specific for each population.
Among the 7 good practice statements, 3 are identical for both the general population of women and for women living with HIV and 2 are different and specific for each population
more
Globally, 311,000 women die of cervical cancer every year, 85 percent of them
in resource limited regions of the world. To address this grave threat to women,
the WHO made a call to action in 2018, resulting in accelerated plans to improve
cervical cancer control under the elimination threshold w...ith respect to cervical
cancer incidence. As part of WHO’s approach to cervical cancer control, availability of high quality,
affordable medical devices for HPV screening, and treatment of precancerous
lesions in low resource settings is indispensable.
more
Multizentrische Analyse des Erkrankungsspektrums und der Versorgungsqualität anhand dezentralisierter Routinedaten des Verbunds PriCarenet
Health Equity Studies & Migration Report Series 2021-03
Hendra virus (HeV) continues to pose a serious public health concern as spillover events occur sporadically. Terminally ill horses can exhibit a range of clinical signs including frothy nasal discharge, ataxia or forebrain signs. Early signs, if detected, can include depression, inappetence, colic o...r mild respiratory signs. All unvaccinated ill horses in areas where flying foxes exist, may potentially be infected with HeV, posing a significant risk to the veterinary community. Equivac® HeV vaccine has been fully registered in Australia since 2015 (and under an Australian Pesticides and Veterinary Medicines Authority special permit since 2012) for immunization of horses against HeV and is the most effective and direct solution to prevent disease transmission to horses and protect humans. No HeV vaccinated horse has tested positive for HeV infection. There is no registered vaccine to prevent, or therapeutics to treat, HeV infection in humans. Previous equine HeV outbreaks tended to cluster in winter overlapping with the foaling season (August to December), when veterinarians and horse owners have frequent close contact with horses and their bodily fluids, increasing the chance of zoonotic disease transmission. The most southerly case was detected in 2019 in the Upper Hunter region in New South Wales, which is Australia's Thoroughbred horse breeding capital. Future spillover events are predicted to move further south and inland in Queensland and New South Wales, aligning with the moving distribution of the main reservoir hosts. Here we (1) review HeV epidemiology and climate change predicted infection dynamics, (2) present a biosecurity protocol for veterinary clinics and hospitals to adopt, and (3) describe diagnostic tests currently available and those under development. Major knowledge and research gaps have been identified, including evaluation of vaccine efficacy in foals to assess current vaccination protocol recommendations.
more
Servicios de Salud locales, distritales, regionales y Unidades de salud de la Familia.
Esta carpeta ofrece información básica acerca de la estrategia de tamizaje basada en el test de VPH. Tiene como principales destinatariosa los integrantes del equipo de salud que realizan las tomas de las muestras para el tamizaje en las provincias que incorporaron esta nueva tecnología [ginecól...ogas/os, Lic. en obstetricia,obstétricas/os, médicas/os generalistas, enfermeras/os, etc.].
more
Cervical cancer is the fourth most common cancer in women worldwide in 2018, with 570,000 new cases and 311,000 deaths occurring annually.T he highest incidence rates are in Southern Africa, Eastern Africa, SubSaharan Africa, Western Africa, Melanesia, and Middle Africa . It also ranks as the leadin...g cause of cancer-related death in most African countries. More than 85% of these deaths occur in low- and middle-income countries . In addition, women living with human immunodeficiency virus (HIV) are six times as likely to have cervical cancer
more
WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines.
Updated risk rates for hospital admission in patients with non-severe COVID-19
The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19.
The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients.
This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines:
**High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%.
**Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%.
Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk.
Review of COVID-19 treatments for people with non-severe COVID-19
WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022.
If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead.
WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission.
For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol.
WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials.
The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials.
more
The guidance document provides a set of indicators for assessing the status of development, implementation and monitoring of key policy interventions for prevention and control of NCDs and injuries. It promotes city-level evidence based decision-making processes to identify gaps and take appropriate...s actions to strengthen responses. Additionally, using the standardized indicators can facilitate cross-city learning, sharing best practices and lessons learnt in implementing various policy interventions.
more